Sugi Predict

Sugi Predict / Targets / BID

BID

BH3-interacting domain death agonist · P55957 · BID on Sugi Atlas →

36,635 patent compounds predicted against BID, 20,125 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Anacardic Acid Anacardic Acid (SCHEMBL627981) 1.00 7/20
SCHEMBL300853 SCHEMBL300853 0.97 7/20
Gingkolic Acid Gingkolic Acid (SCHEMBL163525) 0.95 7/20
SCHEMBL154719 SCHEMBL154719 0.85 7/20
Anacardic Acid Anacardic Acid (SCHEMBL154720) 0.73 7/20
SCHEMBL23277 SCHEMBL23277 0.72 7/20
SCHEMBL300614 SCHEMBL300614 0.72 7/20
SCHEMBL301487 SCHEMBL301487 0.72 7/20
SCHEMBL485756 SCHEMBL485756 0.72 7/20
SCHEMBL244743 SCHEMBL244743 0.70 7/20
SCHEMBL574679 SCHEMBL574679 0.65 7/20
SCHEMBL409185 SCHEMBL409185 0.62 7/20
SCHEMBL211983 SCHEMBL211983 0.58 7/20
SCHEMBL105964 SCHEMBL105964 0.61 6/20
SCHEMBL315846 SCHEMBL315846 0.61 6/20
SCHEMBL632247 SCHEMBL632247 0.61 6/20
Acrylic Acid Acrylic Acid (SCHEMBL111782) 0.60 6/20
Methacrylic Acid Methacrylic Acid (SCHEMBL112437) 0.60 6/20
SCHEMBL97903 SCHEMBL97903 0.59 6/20
SCHEMBL574314 SCHEMBL574314 0.59 6/20

Clinical trials — most relevant to BID by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery PHASE4COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Disulfiram in Rheumatoid Arthritis PHASE2NOT_YET_RECRUITING
BL-8040 Addition to Consolidation Therapy in AML Patients PHASE2UNKNOWN
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML PHASE2RECRUITING
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors PHASE1UNKNOWN
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS PHASE1RECRUITING
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma PHASE1COMPLETED
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors PHASE1COMPLETED
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE1SUSPENDED
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome PHASE1COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
Meclizine for Hepatocellular Carcinoma PHASE1COMPLETED
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies PHASE1WITHDRAWN
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML PHASE1RECRUITING
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML nanRECRUITING
Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors nanCOMPLETED
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission nanRECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BID binder may also engage these)

ProteinNameSimilarity
Q4JHS0 — 1.000 Q4JHS0 →
P70444 — 0.995 P70444 →
Q9JLT6 — 0.993 Q9JLT6 →
Q8JGM8 — 0.992 Q8JGM8 →
BCL2L1 Bcl-2-like protein 1 0.977 landscape →
BAK1 Bcl-2 homologous antagonist/killer 0.977 landscape →
O77737 — 0.975 O77737 →
O08734 — 0.975 O08734 →
Q64373 — 0.973 Q64373 →
Q07816 — 0.972 Q07816 →
BAX Apoptosis regulator BAX 0.971 landscape →
Q5XJS0 — 0.971 Q5XJS0 →
P59017 — 0.971 P59017 →
Q9Z0F3 — 0.971 Q9Z0F3 →
Q6PCG6 — 0.970 Q6PCG6 →
Q6DC66 — 0.970 Q6DC66 →
BCL2L13 Bcl-2-like protein 13 0.970 landscape →
Q4QQM5 — 0.970 Q4QQM5 →
Q24JP3 — 0.970 Q24JP3 →
P53563 — 0.970 P53563 →
Q9H6J7 — 0.970 Q9H6J7 →
Q0P4Z1 — 0.970 Q0P4Z1 →
O02703 — 0.969 O02703 →
Q4R5A4 — 0.969 Q4R5A4 →
Q8NAN2 — 0.969 Q8NAN2 →
Q5RC14 — 0.969 Q5RC14 →
Q8WWU5 — 0.969 Q8WWU5 →
Q4KLN4 — 0.969 Q4KLN4 →
Q32LC2 — 0.969 Q32LC2 →
Q8BK03 — 0.968 Q8BK03 →